And there could be more positive developments ahead.

Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment ...

Key Stats for Amgen StockPrice change for Amgen stock in last 1 year: 43%$AMGN Stock Price as of Sep. 22: $41052-Week High: $447$AMGN Stock Price Target: $388What Happened?Amgen (AMGN) stock rose ...

Shares of Amgen Inc. advanced 4.34% to $410.24 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index remaining mostly unchanged at 7,764.64 and ...

Amgen (AMGN) stock jumped 4% Tuesday after its dazodalibep Phase 3 Sjögren's trial met its primary endpoint with no approved ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning.

Amgen ( AMGN) dropped just over 10% on Tuesday after a late-stage cardiovascular trial failure at Novartis raised concerns about the outlook for Amgen's own olpasiran program. The stock closed at $393 ...

Amgen has just paid its Q2 2026 dividend while Wall Street’s stance remains broadly neutral. Here is how the biotech group positions itself and what current analyst opinions and valuation markers ...

Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.

Amgen (AMGN) stock rose 4% after dazodalibep met Phase 3 trial goals for Sjögren's disease, with no FDA-approved competitors currently available.